Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2004-002376-42-IT
EUCTR2004-002376-42-IT
Active, Not Recruiting
N/A

PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER

G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 sites36 target enrollmentApril 21, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsXELODA 120 CPR RIV. 500MG

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
Enrollment
36
Status
Active, Not Recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 21, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16
Active, Not Recruiting
N/A
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-001421-34-ATniversität zu Köln16
Recruiting
N/A
Randomized phase II study of chemoimmunotherapy with or without metformin as a first-line treatment in patients with squamous cell lung carcinomaNeoplasms
KCT0008659ational Cancer Center70
Active, Not Recruiting
N/A
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemia
EUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
Active, Not Recruiting
Phase 1
Study of chemotherapy and immunotherapy before and after surgery inpatients with non-small cell lung cancer whose tumor is located in theupper part of the lungs
CTIS2024-512359-19-00Fundacion GECP40